Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7723494 | 0.98 | OPRM1 (0.48) | OPRM1SSTR4HTR2AHDAC1POLB | |
| SCHEMBL17188052 | 0.91 | HTR2A (0.50) | OPRM1SSTR4HTR2AHDAC1POLB | |
| SCHEMBL2363242 | 0.87 | HTT (0.48) | OPRM1SSTR4HDAC1POLBALDH1A1 | |
| SCHEMBL2231946 | 0.86 | POLB (0.57) | OPRM1SSTR4HTR2AHDAC1POLB | |
| SCHEMBL4630876 | 0.86 | OPRM1 (0.47) | OPRM1SSTR4HTR2AHDAC1POLB | |
| Benzene SCHEMBL27461502 | 0.86 | OPRM1 (0.47) | OPRM1SSTR4HTR2AHDAC1POLB | |
| Hydrochloric Acid SCHEMBL2479293 | 0.85 | POLB (0.56) | OPRM1SSTR4HTR2AHDAC1POLB | |
| SCHEMBL9786501 | 0.85 | HDAC1 (0.49) | OPRM1SSTR4HDAC1ALDH1A1KDM4E | |
| SCHEMBL4631318 | 0.85 | OPRM1 (0.49) | OPRM1SSTR4HTR2AHDAC1POLB | |
| SCHEMBL4630574 | 0.83 | SSTR4 (0.45) | OPRM1SSTR4HTR2AHDAC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1133622-C | Ureidopiperidine derivatives as human NK3Selective antagonists of receptors | ʥŵ��-�ϳ�ʵ���ҹ�˾ | 2004-01-07 | — | — | CN | claimed |
| EP-1140923-B1 | METHOD FOR PREPARING (R)- (+) -3 1- 2-( 4-BENZOYL- 2-(3,4- DIFLUOROPHENYL)MORPHOLIN- 2-YL)ETHYL]- 4-PHENYLPIPERIDIN -4-YL -1,1- DIMETHYLUREA, ITS SALTS SOLVATES AND/OR HYDRATES | SANOFI SYNTHELABO (FR) | 2003-03-05 | — | — | EP | claimed |
| US-6465489-B1 | SUCH AS 1-BENZOYL-3-(3,4-DICHLOROPHENYL)-3-(3-(4-(N',N'-DIMETHYLUREIDO)-4 -PHENYLPIPERIDIN-1-)PROPYL)PIPERIDINE; PSYCHIATRIC AND PSYCHOSOMATIC ILLNESSES, HYPERTENSION, CENTRAL OR PERIPHERAL PATHOLOGY | SANOFI-SYNTHELABO (FR) | 2002-10-15 | — | — | US | claimed |
| US-6392039-B1 | COUPLING; SALT FORMATION | SANOFI-SYNTHELABO (FR) | 2002-05-21 | — | — | US | claimed |
| CN-1329594-A | Ureidopiperidine derivatives as human NK3Selective antagonists of receptors | SANOFI SYNTHELABO (FR) | 2002-01-02 | — | — | CN | claimed |
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| WO-2022237178-A1 | BICYCLIC HETEROARYL DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2022-11-17 | — | — | WO | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
| EP-2760862-A1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013045413-A1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2013-04-04 | — | — | WO | disclosed |
| US-6465489-B1 | SUCH AS 1-BENZOYL-3-(3,4-DICHLOROPHENYL)-3-(3-(4-(N',N'-DIMETHYLUREIDO)-4 -PHENYLPIPERIDIN-1-)PROPYL)PIPERIDINE; PSYCHIATRIC AND PSYCHOSOMATIC ILLNESSES, HYPERTENSION, CENTRAL OR PERIPHERAL PATHOLOGY | SANOFI-SYNTHELABO (FR) | 2002-10-15 | — | — | US | disclosed |
| US-6392039-B1 | COUPLING; SALT FORMATION | SANOFI-SYNTHELABO (FR) | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | OPRM1 4615/4885SSTR4 4611/4885HTR2A 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.